NGL Fine-Chem Limited (NGLFINE.NS)
INR 1122.3
(-4.99%)
INR 1122.3
(-4.99%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 324.42 Million INR | 6.44% |
| 2022 | 304.78 Million INR | 1.59% |
| 2021 | 300.01 Million INR | 82.4% |
| 2020 | 164.48 Million INR | -41.74% |
| 2019 | 282.31 Million INR | 3.94% |
| 2018 | 271.62 Million INR | 1.86% |
| 2017 | 266.67 Million INR | 30.76% |
| 2016 | 203.94 Million INR | 59.91% |
| 2015 | 127.53 Million INR | -3.32% |
| 2014 | 131.91 Million INR | -10.99% |
| 2013 | 148.19 Million INR | 24.53% |
| 2012 | 119 Million INR | 36.01% |
| 2011 | 87.49 Million INR | 38.71% |
| 2010 | 63.07 Million INR | 24.93% |
| 2009 | 50.49 Million INR | 21.96% |
| 2008 | 41.39 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 324.42 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 324.42 Million INR | 6.44% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 272.1 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 304.78 Million INR | 0.0% |
| 2022 FY | 304.78 Million INR | 1.59% |
| 2022 Q2 | 267.29 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 300.01 Million INR | 0.0% |
| 2021 Q2 | 192 Million INR | 0.0% |
| 2021 FY | 300.01 Million INR | 82.4% |
| 2020 Q2 | 244.52 Million INR | 0.0% |
| 2020 FY | 164.48 Million INR | -41.74% |
| 2020 Q4 | 164.48 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q2 | 241.71 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 282.31 Million INR | 3.94% |
| 2019 Q4 | 282.31 Million INR | 0.0% |
| 2018 FY | 271.62 Million INR | 1.86% |
| 2018 Q4 | 271.62 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 261.28 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q4 | 266.67 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 266.67 Million INR | 30.76% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 225.55 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 203.94 Million INR | 59.91% |
| 2016 Q4 | 246.42 Million INR | 0.0% |
| 2016 Q2 | 118.12 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q2 | 132.42 Million INR | 0.0% |
| 2015 FY | 127.53 Million INR | -3.32% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 127.53 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 FY | 131.91 Million INR | -10.99% |
| 2014 Q4 | 111.61 Million INR | 0.0% |
| 2014 Q2 | 126.68 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 148.19 Million INR | 24.53% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 119.69 Million INR | 0.0% |
| 2013 Q4 | 148.19 Million INR | 0.0% |
| 2012 Q4 | 119 Million INR | 0.0% |
| 2012 FY | 119 Million INR | 36.01% |
| 2011 Q4 | 87.49 Million INR | 0.0% |
| 2011 FY | 87.49 Million INR | 38.71% |
| 2010 FY | 63.07 Million INR | 24.93% |
| 2009 FY | 50.49 Million INR | 21.96% |
| 2008 Q4 | 41.39 Million INR | 0.0% |
| 2008 FY | 41.39 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Abbott India Limited | 832.3 Million INR | 61.021% |
| Cipla Limited | 5.59 Billion INR | 94.201% |
| Gland Pharma Limited | 3.72 Billion INR | 91.283% |
| GlaxoSmithKline Pharmaceuticals Limited | 186.65 Million INR | -73.814% |
| Kopran Limited | 992.28 Million INR | 67.305% |
| Marksans Pharma Limited | 2.44 Billion INR | 86.707% |
| Pfizer Limited | 945.4 Million INR | 65.684% |
| Sanofi India Limited | 190 Million INR | -70.749% |
| SMS Pharmaceuticals Limited | 2.8 Billion INR | 88.445% |
| TTK Healthcare Limited | 228.1 Million INR | -42.225% |